Zylorion

Zylorion is a private Canadian biopharmaceutical company focused on developing neuroplasticity-based treatments for brain disorders. Its lead program, ZYL-314, is a patented small-molecule drug candidate designed to enhance BDNF/TrkB signaling, with current company materials emphasizing potential use in early Alzheimer's disease and mild cognitive impairment. The company presents ZYL-314 as the basis of a broader platform for additional compounds, formulations, and combination approaches in neurodegenerative and neuropsychiatric conditions. Zylorion appears to have evolved from an earlier psychedelic and mental-health-therapy positioning under the PsiloTec name toward a more focused neurodegeneration strategy. The company is private, active, and headquartered in Calgary, Alberta.